Latest Research And Development News

Page 2 of 115
Vmoto sold 4,881 electric motorcycles and mopeds in the September quarter, up 80% year on year, while firm orders point to another busy three months. The company is expanding beyond Europe, but the growth push is also drawing on cash, bank facilities and ongoing investment in capacity.
Victor Sage
Victor Sage
6 Nov 2026
AVITA Medical has raised its 2026 revenue guidance for a second time after third-quarter revenue climbed 53% year on year. The company also drew a further US$10 million under its credit facility and removed its going-concern qualification, although it remains loss-making and highly leveraged.
Victor Sage
Victor Sage
6 Nov 2026
Zoetis lifted its full-year adjusted earnings outlook after a mixed third quarter, but US companion animal revenue fell 8% amid price sensitivity, competition and generic pressure. The animal health group also reported an 18% drop in GAAP net income and a US$89 million impairment charge.
Ada Torres
Ada Torres
5 Nov 2026
Edwards Lifesciences delivered stronger-than-expected third-quarter growth and lifted its full-year 2026 outlook, led by a sharp rise in mitral and tricuspid therapies. A US$220.2 million impairment charge remains a notable counterpoint to the upbeat operating performance.
Ada Torres
Ada Torres
5 Nov 2026
Ocean Sciences has secured firm commitments for a $700,000 placement to fund its Indonesian seaweed operations, innovation centre and research pipeline. The raising comes with a substantial package of options, while a further loyalty offer could add to the company’s future capital structure.
Victor Sage
Victor Sage
4 Nov 2026
Jack Henry delivered a stronger-than-expected fiscal first quarter, with revenue, operating income and earnings per share all accelerating year on year. Cloud, card, digital and faster-payments demand supported the result, while buybacks and higher borrowings shaped the capital picture.
Sophie Babbage
Sophie Babbage
4 Nov 2026
Arista Networks delivered third-quarter revenue well above its own guidance, with sales reaching US$3.66 billion and GAAP net income hitting US$1.56 billion. The networking specialist is now guiding to as much as US$4.0 billion in fourth-quarter revenue as it expands its AI infrastructure portfolio.
Sophie Babbage
Sophie Babbage
4 Nov 2026
Amgen delivered 8% third-quarter revenue growth and a 19% increase in GAAP diluted EPS, while newer medicines continued to expand. The result came alongside sharp declines in Prolia and XGEVA sales from biosimilar competition and a busy pipeline of late-stage programmes.
Victor Sage
Victor Sage
4 Nov 2026
Pfizer has lifted its 2026 revenue and adjusted earnings guidance after a quarter in which newer and acquired medicines grew strongly enough to offset steep declines in COVID-19 products. Overall revenue was flat, while reported net income fell 8%.
Victor Sage
Victor Sage
4 Nov 2026
Vertex has raised its full-year 2026 revenue guidance after third-quarter sales climbed 12%, but the Crinetics acquisition sharply increased costs and debt. The next major test arrives on 30 November, when US regulators are due to rule on povetacicept for IgA nephropathy.
Ada Torres
Ada Torres
3 Nov 2026
Noxopharm has secured a $1.5 million placement and agreed to convert $3.78 million of shareholder notes as it prepares to test SOF-SKN in cutaneous lupus patients. The funding eases an immediate cash constraint, but the package also brings substantial dilution and remains partly subject to shareholder approval.
Ada Torres
Ada Torres
2 Nov 2026
Proteomics International has launched a discounted A$5 million share purchase plan as it moves from product development into commercial rollout. Eligible shareholders can buy shares at A$0.10 and may receive a free attaching option, subject to approval.
Ada Torres
Ada Torres
2 Nov 2026

Browse the archive

Full archive